



RECEIVED

JAN 28 2003

BOX PATENT

TECH CENTER 1600/2900

Attorney Docket No. 24390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

SHINITZKY et al.

Examiner: S. Turner

Serial No.: 09/647,457

Art Unit: 1647

Filed: November 29, 2000

For: **ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON
A NEW PEPTIDE**

16/E
MgJ
2/4/03

SEQUENCE LISTING SUBMISSION STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Notice to Comply with Sequence Requirements which was mailed December 26, 2002, with a one-month period for response. A new Sequence Listing is due to be filed by January 26, 2003. Accordingly, this new Sequence Listing is timely filed within the period set for reply by the Examiner.

In connection with the Sequence Listing submitted herewith, the undersigned attorney hereby states that:

- 1) The submission, filed herewith in accordance with 37 CFR 1.821(g), does not include new matter; and
- 2) The content of the attached paper copy and the attached computer readable copy of the Sequence Listing are the same.

Date: January 26, 2003

NATH & ASSOCIATES PLLC
1030 15th Street NW, 6th Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396

GMN:JBG/SMM\seq.state

Respectfully submitted,
NATH & ASSOCIATES PLLC

Gary M. Nath
Reg. No. 26,965
Joshua B. Goldberg
Reg. No. 44,126
Customer No. 20529

01P
JAN 24 2003
PATENT & TRADEMARK OFFICE

Application No.: _____

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: *Applicant's amendment to claim 1 presents new peptide structures which lack compliance. Sequences are required to represent each of the designated peptide structures including the generic sequence.*
Applicant Must Provide:
 - ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
 - ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
 - ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY